Effect of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors on Lipoprotein(a) Levels: An Umbrella Review of Meta-analyses of Randomized Controlled Trials.

Saved in:
Bibliographic Details
Title: Effect of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors on Lipoprotein(a) Levels: An Umbrella Review of Meta-analyses of Randomized Controlled Trials.
Authors: Qiao W; Department of Endocrinology and Metabolism, NHC Key Laboratory of Diagnosis and Treatment of Thyroid Disease, The Institute of Endocrinology, The First Hospital of China Medical University, Shenyang, Liaoning, China., Feng Y; Department of Endocrinology and Metabolism, NHC Key Laboratory of Diagnosis and Treatment of Thyroid Disease, The Institute of Endocrinology, The First Hospital of China Medical University, Shenyang, Liaoning, China., Wen Z; Department of Neurosurgery, The First Hospital of China Medical University, Shenyang, China., Dou L; Department of Gynecology, The First Hospital of China Medical University, Shenyang, China. doulei840416@163.com., Li Y; Department of Endocrinology and Metabolism, NHC Key Laboratory of Diagnosis and Treatment of Thyroid Disease, The Institute of Endocrinology, The First Hospital of China Medical University, Shenyang, Liaoning, China. yzli87@cmu.edu.cn.
Source: Drugs [Drugs] 2026 Feb; Vol. 86 (2), pp. 217-230. Date of Electronic Publication: 2026 Jan 19.
Publication Type: Journal Article; Systematic Review
Journal Info: Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 7600076 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1950 (Electronic) Linking ISSN: 00126667 NLM ISO Abbreviation: Drugs Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1179-1950
DOI:10.1007/s40265-025-02274-x